P-PEAKS UTI Personalized-Phage Against E. Coli with IV Antibiotic to Knockout Stable Biofilms in Urinary Tract Infections
- Coordinator
- Unity Health Toronto, Canada
- Runs
- 1 June 2026 to 31 May 2030
- Status
- Running
- EU funding
- €15.6m
- Total cost
- —
- Partners
- 20 organisations in 12 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101289070
What the project is doing
In the project's own words, from its summary on CORDIS.
P-PEAKS UTI is a multicenter, intercontinental Phase II randomized controlled trial evaluating the safety, efficacy, and feasibility of personalized bacteriophage therapy in combination with intravenous beta-lactam antibiotics for the secondary prevention of recurrent urinary tract infections (rUTIs) caused by Escherichia coli in female patients . The study will recruit 216 participants across 9 clinical sites, including high-risk renal transplant recipients.
Phage therapy or placebo will be administered via oral (day 1 and 2), bladder instillation (day 1), and topical/vaginal routes all over 5 days. Both arms will receive a single dose of IV antibiotic on day 2 to enhance bacterial clearance and biofilm disruption. This combination strategy leverages potential synergy between phages and antibiotics, aiming to reduce recurrence rates and antibiotic use. The project integrates AI-based phage-host prediction, GMP and Magistral phage production, and standardized susceptibility testing aligned with EUCAST guidelines.
It investigates phage immunogenicity, microbiome dynamics, and pharmacokinetics/pharmacodynamics to inform future personalized antimicrobial strategies. P-PEAKS UTI also performs health economic analysis to quantify cost-effectiveness of phage therapy in urinary tract infections compared to standard antibiotic treatment and engages patients to address stigma and acceptability of phage therapy. It contributes to regulatory science by generating quantifiable, replicable data to support future market authorization of phage therapies and informs policy through collaboration with EMA and national agencies.
In the longer term, we aim to deliver an improved, effective and meaningful solution for the prevention of recurrent UTIs in female patients improving their health outcomes and quality of life. This will also strengthen healthcare systems’ capacity to combat antimicrobial resistance and empower citizens with knowledge-based alternatives to antibiotics.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Unity Health Toronto | Toronto | Canada | Coordinator |
| Europaischer Nierenpatientenverband | Wien | Austria | Participant |
| Patrimoine De L'ecole Royale Militaire - Vermogen Van De Koninklijke Militaire School | Bruxelles / Brussel | Belgium | Participant |
| Qeen Biotechnologies Inc. | Gatineau | Canada | Participant |
| Universite Laval | Quebec | Canada | Participant |
| University of Calgary | Calgary Alberta | Canada | Participant |
| Philipps Universitaet Marburg | Marburg | Germany | Participant |
| Sihtasutus Tartu Ulikooli Kliinikum | Tartu | Estonia | Participant |
| Tartu Ulikool | Tartu | Estonia | Participant |
| Fundacion Publica Galega De Investigacion Biomedica Inibic | A Coruna | Spain | Participant |
| Assistance Publique Hopitaux De Paris | Paris | France | Participant |
| Hadassah Medical Organization | Jerusalem | Israel | Participant |
| The Hebrew University of Jerusalem | Jerusalem | Israel | Participant |
| Azienda Ospedaliero Universitaria Pisana | Pisa | Italy | Participant |
| Lunds Universitet | Lund | Sweden | Participant |
| Micron Research Limited | Ely | United Kingdom | Participant |
| University College London | London | United Kingdom | Participant |
| Baylor College of Medicine | Houston Tx | United States | Participant |
| Mayo Clinic | Rochester | United States | Participant |
| The Regents of the University of California | Oakland | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI